

Regimen Reference Order – CLL – iBRUtinib

ARIA: CLL – [iBRUtinib]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Proceed with treatment if:

ANC equal to or greater than $0.5 \times 10^9/L$ AND Platelets equal to or greater than $25 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
allopurinol*	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles * Only patients at risk of tumor lysis syndrome will be prescribed allopurinol

Treatment Regimen – CLL – iBRUtinib

Drug	Dose	CCMB Administration Guideline
iBRUtinib	420 mg	Orally once daily (with or without food) (Self-administered at home)
iBRUtinib (Imbruvica®) available dosage strength: 140 mg capsule Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

- CBC, biochemistry once weekly for 8 weeks then monthly thereafter as per physician order
- Monitor pulse for tachycardia and irregular rhythm once weekly for the first 8 weeks, then prior to each cycle
- Order EKG to assess for atrial fibrillation if tachycardia or irregular rhythm present

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

INSTRUCTIONS FOR PATIENT

- Patients should notify clinic prior to starting any new medication. iBRUtinib has potential for drug-drug interactions
- Avoid grapefruit and grapefruit juice
- Patient should report bleeding, palpitations, syncope, and skin or nail changes
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on iBRUtinib

ADDITIONAL INFORMATION

- Lymphocytosis is expected with therapy and will not be considered evidence of disease progression unless accompanied by other clinical signs of disease progression (i.e. increasing lymphadenopathy, constitutional symptoms, etc.)
- iBRUtinib will be dispensed by CancerCare Manitoba Pharmacy